Health Characteristics of Elderly North Korean Defectors: 2006-2016 at National Medical Center

We analyzed the dynamics of congenital cleft lip and palate in children and studied the archival data of the National Medical Center Shifobakhsh (Dushanbe) of the Republic of Tajikistan on the incidence of outpatient visits due to this abnormality in the Republic of Tajikistan over the period from 2009 to 2019. The number of children born with congenital cleft has been increasing for the last ten years. We found out this pathology to develop in families with in-and-in marriage, it also depends upon the sex of a child. Boys are more prone to maxillofacial anomalies.

Download Full-text

The VP7 Genes of Two G9 Rotaviruses Isolated in 1980 from Diarrheal Stool Samples Collected in Washington, DC, Are Unique Molecularly and Serotypically

Journal of Virology ◽

10.1128/jvi.02537-07 ◽

2008 ◽

Vol 82 (8) ◽

pp. 4175-4179 ◽

Cited By ~ 14

Author(s):

Dianjun Cao ◽

Norma Santos ◽

Ronald W. Jones ◽

Masatoshi Tatsumi ◽

Jon R. Gentsch ◽

...

Keyword(s):

Retrospective Study ◽

Amino Acid ◽

Amino Acid Sequence ◽

Medical Center ◽

Washington Dc ◽

Sequence Analyses ◽

National Medical ◽

Lineage 2 ◽

Stool Samples ◽

Vp7 Gene

ABSTRACT In a retrospective study of archival diarrheal stool samples collected from 1974 to 1991 at Children's Hospital National Medical Center, Washington, DC, we detected three genotype G9P[8] viruses in specimens collected in 1980, which represented the earliest human G9 viruses ever isolated. The VP7 genes of two culture-adapted 1980 G9 viruses were phylogenetically related closely to the lineage 2 G9 virus VP7 gene. Unexpectedly, however, the VP7s of the 1980 G9 viruses were more closely related serotypically to lineage 3 VP7s than to lineage 2 VP7, which may be supported by amino acid sequence analyses of the VP7 proteins.

Download Full-text

The National Medical Center in Korea

American Journal of Health-System Pharmacy ◽

10.1093/ajhp/24.12.704 ◽

1967 ◽

Vol 24 (12) ◽

pp. 704-707

Author(s):

Knud Christensen

Keyword(s):

Medical Center ◽

National Medical

Download Full-text

Late Congestive Heart Failure After Hematopoietic Cell Transplantation

Journal of Clinical Oncology ◽

10.1200/jco.2008.17.7428 ◽

2008 ◽

Vol 26 (34) ◽

pp. 5537-5543 ◽

Cited By ~ 81

Author(s):

Saro H. Armenian ◽

Can-Lan Sun ◽

Liton Francisco ◽

Julia Steinberger ◽

Seira Kurian ◽

...

Keyword(s):

Heart Failure ◽

Congestive Heart Failure ◽

Cell Transplantation ◽

Hematopoietic Cell Transplantation ◽

Medical Center ◽

Multivariable Analysis ◽

Hematopoietic Cell ◽

Sampling Frame ◽

National Medical ◽

Chronic Comorbidities

Purpose To examine the independent roles of pre–hematopoietic cell transplantation (HCT) therapeutic exposures, transplantation-related conditioning, and comorbidities (pre- and post-HCT) in the development of late congestive heart failure (CHF) after HCT. Methods This was a nested case-control design. Individuals with late CHF (diagnosed ≥ 1 year after HCT) were identified from a cohort of 2,938 1+ year survivors who underwent transplantation at City of Hope National Medical Center, Duarte, CA. This cohort formed the sampling frame for selecting controls (without CHF) matched for age and year of HCT, donor source (allogeneic v autologous), and length of follow-up. Results Sixty patients with late CHF were identified; median age at HCT was 45.3 years (range, 16.6 to 68.6 years); median time to CHF was 3.0 years (range, 1.03 to 18.9 years); 68% received autologous HCT. Median ejection fraction was 36.9% (range, 15% to 53%). Compared with matched controls (n = 166), patients with late CHF received more cycles of pre-HCT chemotherapy (8.6 v 4.9 cycles; P < .01), had greater body mass index at HCT (28.4 v 26.2 kg/m2; P = .01), greater lifetime anthracycline exposure (285.3 v 175.6 mg/m2; P < .01), and were more likely to have multiple chronic comorbidities (30.0% v 13.9%; P < .01). Multivariable analysis revealed number of pre-HCT chemotherapy cycles (odds ratio [OR] = 1.2; P < .01), anthracycline dose ≥ 250 mg/m2 (OR = 3.2; P = .05), and two or more chronic comorbidities (OR = 4.3; P = .01) to be independently associated with late CHF. Conclusion Pre-HCT exposure to anthracyclines and presence of comorbidities are primarily responsible for the risk associated with late CHF after HCT. Conditioning-related therapeutic exposure does not contribute significantly to the risk. These results form the basis for identifying high-risk individuals for targeted surveillance, as well as developing preventive strategies in the form of aggressive management of comorbidities.

Download Full-text

A Retrospective Analysis of Using Pre-Transplant Functional FDG-PET to Predict for Relapse and Survival in Relapsed Hodgkin Lymphoma (HL) Patients Undergoing Autologous Hematopoietic Cell Transplantation (AHCT).

Blood ◽

10.1182/blood.v114.22.1225.1225 ◽

2009 ◽

Vol 114 (22) ◽

pp. 1225-1225

Author(s):

Robert Chen ◽

Joycelynne Palmer ◽

Leslie Popplewell ◽

Ni-Chun Tsai ◽

Amrita Krishnan ◽

...

Keyword(s):

Retrospective Analysis ◽

Relapse Rate ◽

Fdg Pet ◽

Medical Center ◽

Salvage Chemotherapy ◽

Ct Scans ◽

Free Survival ◽

Positive Group ◽

National Medical ◽

Fdg Pet Scan

Abstract Abstract 1225 Poster Board I-247 Background High dose chemotherapy and AHCT can effectively salvage 50-60% of relapsed HL patients with chemosensitive disease and about 25-40% of patients with chemorefractory disease. Patients with chemosensitive disease at time of AHCT will have improved progression free survival and decreased relapse rate. Traditionally, standard response criteria use conventional computed tomography (CT) scans as the radiographic assessment tool. However, CT scans often can not distinguish between residual disease and scar tissue in malignant lymphomas status post chemotherapy. Functional imaging with FDG-PET is more sensitive and specific than CT scans for characterization of residual mass after chemotherapy, and may offer more prognostic information. The predictive value of FDG-PET on clinical outcomes among HL patients who undergo AHCT has been reported by relatively few centers. We conducted a retrospective analysis of 41 consecutive HL patients who had FDG-PET scan after at least two cycles of salvage chemotherapy and before undergoing AHCT at City of Hope National Medical Center. Aim To determine the prognostic impact of pre-transplant functional FDG-PET in predicting the outcome of AHCT in relapsed HL. Methods A total of 41 consecutive HL patients who had FDG-PET scan after at least two cycles of salvage chemotherapy and before undergoing AHCT at City of Hope National Medical Center between January 2004 and December 2008 were included in this analysis. Results Patient characteristics show median age is 36. 34 patients were chemosensitive at time of AHCT. 31 patients received BCNU/VP-16/CTX, 9 patients received BCNU/VP-16/MEL/Ara-C, and 1 patient received fTBI/VP-16/CTX. Median number of prior regimen is 2. 11 patients received radiation at induction. The patients were then categorized into FDG-PET positive (N=21) and negative (N=20) groups. The median follow-up for all patients after AHCT was 24.1 months (1.3, 54.2). The disease free survival (DFS) at 2 years for FDG-PET positive group was 51.3% (CI 39.7% - 61.8%) compared to 77.9% (CI 58.3% - 89.0%) for the FDG-PET negative (p=0.24). The 2-years overall survival (OS) for FDG-PET positive was 73.9% (CI 55.8% - 85.4%) versus 83.5% (CI 62.7% - 93.3%) for FDG-PET negative (p=0.63). There was a trend for lower relapse rate in the FDG-PET negative patients. The probability of relapse at 1 year for FDG-PET positive was 33.3% (CI 21.9% - 48.7%) compared to 11.5% (CI 3.5% - 34.0%) for FDG-PET negative (p= 0.15). There was no significant difference between the FDG-PET positive group versus FDG-PET negative group in terms of gender, time from diagnosis to transplant, conditioning regimen, number of prior regimens, radiation at induction, KPS at AHCT, or stage at diagnosis. Conclusion Pre-transplant functional FDG-PET is useful in predicting the outcomes AHCT in relapsed HL. Our data suggests that a positive FDG-PET prior to AHCT predicts for relapses and decreased DFS. Disclosures No relevant conflicts of interest to declare.

Download Full-text

Molecular Status Evaluation in a Standardized Laboratory in a Cohort of Patients with Chronic Myeloid Leukemia At the Instituto Mexicano Del Seguro Social (IMSS)

Blood ◽

10.1182/blood.v120.21.4452.4452 ◽

2012 ◽

Vol 120 (21) ◽

pp. 4452-4452

Author(s):

Luis A Meillón ◽

Carolina Sandoval-Sanchez ◽

Nancy Delgado-Lopez ◽

Manuel Ayala ◽

Yolanda Lugo ◽

...

Keyword(s):

Kinase Inhibitors ◽

Medical Center ◽

Cytogenetic Response ◽

Molecular Response ◽

Molecular Monitoring ◽

Group V ◽

Group Iii ◽

International Scale ◽

National Medical ◽

Group I

Abstract Abstract 4452 Background: Molecular Monitoring of BCR-ABL through standardized qPCR according to the international scale (IS) has been recently included in the follow-up of CML patients treated with tyrosine kinase inhibitors (TKIs) at the IMSS. The Molecular Biology Laboratory of the “Hospital of Specialties” at the “National Medical Center Siglo XXI”, have recently achieved full standardization of the qPCR technique to the international scale (using a conversion factor provided by Adelaide lab). The use of the IS in the molecular monitoring expressed as Bcr-Abl/Abl ratio in percentage is very important, since this is the best way to adopt appropriate strategies with TKI therapy. Objective: To report the evaluation of molecular status of 485 patients with CML attended at the Instituto Mexicano del Seguro Social using the IS in a reference standardized Mexican laboratory. Material and Methods: From August 2011 to May 2012, peripheral blood samples of 485 patients with CML, were sent to our laboratory. We extracted RNA as previously described. A minimum of 5 ml of whole blood was required in order to maximize optimal results. Then we put these results in our database and classified patient samples in five groups according the percentage of Bcr-Abl/Abl in the international scale: The first group were patients with >10% of Bcr-Abl; the second group were patients with >1–10% of Bcr-Abl; the third group were patients with >0.1–1%; the fourth group were patients with ≤0.1% and the fifth group were patients with undetectable Bcr-Abl transcripts. Results: We found the following distribution: Group I (> 10% Bcr-Abl): 91 patients (18.76%); Group II (>1–10% Bcr-Abl): 65 patients (13.4%); Group III (>0.1–1% Bcr-Abl) 83 patients (17.11%); Group IV (≤0.1% Bcr-Abl) 122 patients (25.15%); and Group V: undetectable Bcr-Abl: 124 patients (25.56%). Conclusion: Fifty percent of CML patients treated with nilotinib, imatinib or dasatinib, have reached a deep molecular response, that is, Major Molecular response (MMR) or better. Another 17% has reached a molecular response (>0.1–1%) that is equivalent to Complete Cytogenetic response (CCyR). This information is very useful for clinicians and should be interpreted individually according the lenght of treatment with TKIs, following current CML guidelines and recommendations. Until now, molecular monitoring using the IS was only possible through sending samples to US laboratories. It is important that Mexican clinicians at our institution have now the opportunity to rely on a Mexican validated and standardized laboratory. The results of the molecular response in this cohort of CML patients can be compared to the data of another countries using the IS. Classifying patients according to their molecular status could help to optimized therapies at our institution. Disclosures: Nacho-Vargas: Novartis Oncology: Employment.

Download Full-text